Filing Flows › Comparisons › VIVS vs SNTI
VivoSim Labs vs Senti Biosciences Holdings: VIVS and SNTI compared
VivoSim Labs is the larger company: $18K of revenue in its latest quarter (Q1 FY27) against $17K for Senti Biosciences Holdings (Q2 2026).
Where the money goes: VIVS and SNTI
VivoSim Labs (VIVS) · Q1 FY27
VivoSim Labs, Q1 FY27: revenue $18K (-51% year over year), net loss $1.3M, operating cash flow −$3.2M. The chart follows the revenue to costs, profit and cash.
Senti Biosciences Holdings (SNTI) · Q2 2026
Senti Biosciences Holdings, Q2 2026: revenue $17K, net loss $12.8M, operating cash flow −$14.2M. The chart follows the revenue to costs, profit and cash.
| VivoSim Labs (VIVS) | Senti Biosciences Holdings (SNTI) | |
|---|---|---|
| Latest quarter | Q1 FY27 | Q2 2026 |
| Revenue | $18K | $17K |
| Revenue growth, Y/Y | -51% | — |
| Operating margin | n/m | n/m |
| Net earnings | −$1.3M | −$12.8M |
| Operating cash flow | −$3.2M | −$14.2M |
Questions
Which is bigger, VivoSim Labs or Senti Biosciences Holdings?
VivoSim Labs is the larger company: $18K of revenue in its latest quarter (Q1 FY27) against $17K for Senti Biosciences Holdings (Q2 2026).
More: VivoSim Labs earnings · how VivoSim Labs makes money · Senti Biosciences Holdings earnings · how Senti Biosciences Holdings makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 12, 2026; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.